Atlas Venture Life Science Advisors, LLC Q3 2024 Filing

Filed November 13, 2024

Portfolio Value

$1.1B

Holdings

14

Report Date

Q3 2024

Filing Type

13F-HR

All Holdings (14 positions)

#	Stock	Shares	Value	% Portfolio	Type
1	DYNDyne Therapeutics, Inc.	8,020,136	$288.1M	26.71%
2	KYMRKymera Therapeutics, Inc.	4,896,462	$231.7M	21.48%
3	THRDThird Harmonic Bio, Inc.	10,907,859	$147.8M	13.70%
4	IRONDisc Medicine, Inc.	2,509,456	$123.3M	11.43%
5	QTTBQ32 Bio, Inc.	2,092,106	$93.3M	8.65%
6	DAWNDay One Biopharmaceuticals, Inc.	6,430,257	$89.6M	8.30%
7	KRROKorro Bio, Inc.	1,137,149	$38.0M	3.52%
8	GBIOGBXGeneration Bio, Co.	8,279,484	$20.5M	1.90%
9	VIGLVigil Neuroscience, Inc.	5,836,874	$19.8M	1.84%
10	TECXTectonic Therapeutics, Inc.	378,447	$11.5M	1.06%
11	—Ikena Oncology, Inc.	5,018,178	$8.7M	0.80%
12	AVTEAerovate Therapeutics, Inc.	1,799,232	$3.8M	0.35%
13	DNTHDianthus Therapeutics, Inc.	76,979	$2.1M	0.20%
14	SPROSpero Therapeutics, Inc.	402,885	$540K	0.05%